“…Additional but not as well-established effect is the ability of cysteinyl LTs to control eosinophil activities, including those related to tissue infiltration. Involvement of cysteinyl LTs in eosinophil influx is an in vivo phenomenon which was firstly demonstrated in guinea-pigs (Chan et al, 1990), but also observed in human (Laitinen et al, 1993) and reinforced by the anti-allergic effects of CysLT1 antagonists which, in addition to inhibiting allergic symptoms, also inhibit eosinophil recruitment during airway allergic inflammation (Peters-Golden, 2008). Even though cysteinyl LTs display negligible eosinophilotactic activity in vitro ( Figure 1 , left panel; Fregonese et al, 2002), cysteinyl LTs contribute to several mechanisms involved in mouting tissue eosinophilia, since: (i) cysteinyl receptor CysLT1 appears to play a role in eosinophilopoeisis, inasmuch as CysLT1 antagonism in vivo limits IL-5-responsive eosinophil differentiation and maturation (Saito et al, 2004); (ii) cysteinyl LTs are able to significantly up-regulate adhesion molecules, such as Mac-1 expression (Fregonese et al, 2002; Saito et al, 2004); (iii) direct administration of LTC 4 induce a rapid and significant reduction in leukocyte rolling velocity, further increasing cell adherence odds (Kanwar et al, 1995); (iv) cysteinyl LTs induce RANTES production from isolated lung cells, which in turn might cause RANTES-driven migration of eosinophils into airways (Kawano et al, 2003).…”